EMEA-001072-PIP01-10-M04 - paediatric investigation plan

alemtuzumab

Key facts

• Invented name:
  • Lemtrada
  • Lemtrada
• Active Substance:
  alemtuzumab
• Therapeutic area:
  Neurology
• Decision number:
  P/0269/2020
• PIP number:
  EMEA-001072-PIP01-10-M04
• Pharmaceutical form(s):
  Concentrate for solution for infusion
• Condition(s) / indication(s):
  Treatment of multiple sclerosis
• Route(s) of administration:
  Intravenous use
• Contact for public enquiries:

  Genzyme Europe B.V.

  Tel: [phone]; E-mail: [e-mail]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  15/07/2020

Decision

P/0269/2020 : EMA decision of 17 July 2020 on the acceptance of a modification of an agreed paediatric investigation plan for alemtuzumab (Lemtrada) (EMEA-001072-PIP01-10-M04)

AdoptedReference Number: EMA/366649/2020